Quratis (348080) Stock Overview

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; dendritic cell-based cell therapy for indications, including cancer, autoimmune, and infectious diseases; and peptide nucleic acid-based antimicrobial agents. The company also offers drugs contract development and manufacturing services. Quratis Inc. was founded in 2016 and is based in Seoul, South Korea.